Drug Development
Chiesi Invests Heavily in Gossamer’s Promising Pulmonary Hypertension Treatment
Chiesi, Gossamer, pulmonary hypertension, drug development, investment, collaboration, GD-001, clinical trials, cardiovascular diseases.
Amgen Discontinues Obesity Program, Shifts Focus to MariTide after Phase 1 Results
Amgen, obesity asset, phase 1 results, MariTide, drug development, biotechnology, clinical trials
BridgeBio Secures $200 Million from Venture Capitalists to Propel Oncology Spinout Beyond KRAS Class
BridgeBio, venture capital, oncology, spinout, KRAS class, cancer treatment, biotechnology, drug development, investment, healthcare.
Federal Trade Commission Challenges Novo Nordisk’s Ozempic and Over 300 ‘Junk’ Patent Listings in FDA Database
FTC, Novo Nordisk, Ozempic, FDA, patent listings, crackdown, junk patents, pharmaceutical industry, intellectual property, drug development.
Enlaza Secures $100M for Groundbreaking Irreversible Protein Binding Technology
Enlaza, funding, investment, protein binding, irreversible, biotechnology, medical research, drug development, therapeutics.
Novartis Invests $180M in PeptiDream to Boost Radiopharmaceutical Development
Novartis, PeptiDream, radiopharmaceuticals, investment, drug development, partnership, targeted therapies, cancer treatment, radioactive isotopes.
Strategic Acquisition, Partnership, and Development of Innovative Assets in Biopharma
Biopharma, Innovative Assets, Acquisition, Partnership, Development, Strategic Decision-Making, Pharmaceutical Industry, Drug Development, Market Trends, Risk Management, Portfolio Diversification
Roche’s Strategic Shift Affects 20% of New Molecules, as Cancer Candidates are Reassessed
Roche, pipeline, rethink, new molecules, cancer candidates, discard pile, strategic shift, pharmaceutical industry, drug development, oncology research
Roche Streamlines Portfolio, Prioritizes High-Impact Projects After Pipeline Reduction
Roche, pharmaceuticals, pipeline, portfolio optimization, high-impact projects, strategic decision, drug development
Incyte Invests in Mast Cell Inhibitors with $750M Escient Acquisition
Incyte, Escient, mast cell inhibitors, acquisition, pharmaceutical, drug development, inflammatory diseases, cancer, fibrosis, $750 million